Nutrients in the intestinal lumen initiate changes in motor function of the gastrointestinal tract. Intestinal lipid acts via a cholecystokinin A receptor- (CC.-AR) and a vagal afferent-dependent pathway. The hypothesis to be tested is that intestinal lipid- induced inhibition of gastric motility is dependent on absorption of lipid by enterocytes, formation and release of chylomicrons and apolipoprotein A-IV (apoA-IV), release of CCK. by apo A-IV and CCK acting on CCK-ARs on intestinal afferent nerve terminals. To test this hypothesis, studies are proposed to determine that: (1) inhibition of gastric emptying by lipid in the intestinal lumen depends on chylomicron formation and release of apo A-IV; (2) release of CCK in response to lipid is dependent on chylomicron formation and release of ap A-IV; (3) activation of vagal afferents in response to intestinal lipid is dependent on release of apo A-IV and CCK-AR activation and (4) to demonstrate the expression of CCK-AR on neuronal elements in the stomach and duodenum and their functional regulation by CCK. The role of chylomicron formation in lipid- induced inhibition of gastric emptying or motility and release of CCK will be determined in rats using the surfactant pluronic L81. Postabsorptive chylomicron products in mesenteric lymph will be given intra-arterially to demonstrate their effectiveness to inhibit gastric motility and act via a CCK-AR- and vagal capsaicin-dependent pathway. The role of apo A-IV in inhibition of gastric motility and CCK release in response to lipid will be determined by in vivo immunoneutralization, removal of apo A-IV from chylous lymph by immunoprecipitation, and by exogenous administration of apo A-I. Lipid-induced inhibition of gastric emptying and release of CCK will be measured in apo A-IV over-expressing and apo A-IV knockout mice. CCK secretion from STC-1 ;cells will be measured in vitro to determine that apo A-IV acts direct on endocrine cells. Intestinal vagal afferent fiber discharge will be measured in response to intestinal perfusion of lipid and exogenous administration of apo A- IV acts directly on endocrine cells. Intestinal vagal afferent fiber discharge will be measured in response to intestinal perfusion of lipid and exogenous administration of apo A-IV and determine that both of these responses are CCK-AR- dependent using the CCK-AR antagonist devazepide. A direct effect of Cck on vagal afferents innervating the gastro-duodenum will be determined by measuring calcium fluxes in response to CCK in nodose neurons in vitro. The cellular sites of expression and origins of Cck-ARs will be determined in immunohistochemical studies using antisera raised to different regions of the rat CCK-AR in tissue from intact, extrinsically denervated or capsaicin treated rats The co- localization of CCK-AR with other enteric neuropeptides, and with neuronal and endocrine CCK will be determined in double labeling experiments. The functional regulation of Cck- Ars in the stomach and duodenum will by investigated using exogenous and endogenous CCK and devazepide. These studies address sensory transduction in the gastrointestinal tract which is important in the regulation of normal digestive function. There is evidence that sensory function of the intestine is altered in pathological conditions such as inflammatory bowel disease, irritable bowel syndrome and obesity. A greater understanding of these sensory mechanisms will help in understanding the pathophysiology of these diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK041004-10
Application #
2859201
Study Section
General Medicine A Subcommittee 2 (GMA)
Program Officer
Hamilton, Frank A
Project Start
1989-08-01
Project End
2004-08-31
Budget Start
1999-09-01
Budget End
2000-08-31
Support Year
10
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Boudry, Gaëlle; Hamilton, M Kristina; Chichlowski, Maciej et al. (2017) Bovine milk oligosaccharides decrease gut permeability and improve inflammation and microbial dysbiosis in diet-induced obese mice. J Dairy Sci 100:2471-2481
Hamilton, M Kristina; Ronveaux, Charlotte C; Rust, Bret M et al. (2017) Prebiotic milk oligosaccharides prevent development of obese phenotype, impairment of gut permeability, and microbial dysbiosis in high fat-fed mice. Am J Physiol Gastrointest Liver Physiol 312:G474-G487
Hamilton, M K; Raybould, H E (2016) Bugs, guts and brains, and the regulation of food intake and body weight. Int J Obes Suppl 6:S8-S14
Ronveaux, Charlotte C; Tomé, Daniel; Raybould, Helen E (2015) Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. J Nutr 145:672-80
de La Serre, Claire B; de Lartigue, Guillaume; Raybould, Helen E (2015) Chronic exposure to low dose bacterial lipopolysaccharide inhibits leptin signaling in vagal afferent neurons. Physiol Behav 139:188-94
Ronveaux, Charlotte C; de Lartigue, Guillaume; Raybould, Helen E (2014) Ability of GLP-1 to decrease food intake is dependent on nutritional status. Physiol Behav 135:222-9
de Lartigue, Guillaume; Ronveaux, Charlotte C; Raybould, Helen E (2014) Deletion of leptin signaling in vagal afferent neurons results in hyperphagia and obesity. Mol Metab 3:595-607
Eisner, Friederike; Martin, Elizabeth M; Küper, Markus A et al. (2013) CCK1-receptor stimulation protects against gut mediator-induced lung damage during endotoxemia. Cell Physiol Biochem 32:1878-90
de Lartigue, Guillaume; Barbier de la Serre, Claire; Espero, Elvis et al. (2012) Leptin resistance in vagal afferent neurons inhibits cholecystokinin signaling and satiation in diet induced obese rats. PLoS One 7:e32967
de Lartigue, Guillaume; Barbier de la Serre, Claire; Espero, Elvis et al. (2011) Diet-induced obesity leads to the development of leptin resistance in vagal afferent neurons. Am J Physiol Endocrinol Metab 301:E187-95

Showing the most recent 10 out of 29 publications